Top Stories
The oral MRGPRX2 antagonist failed a Phase IIb trial in moderate-to-severe atopic dermatitis following earlier disappointment in chronic spontaneous urticaria.
INBRX-106 paired with Merck & Co.'s Keytruda achieved a confirmed overall response rate of 80% in patients with HPV-positive head and neck squamous cell carcinoma (HNSCC).
Brainomix's 360 E-lung software found that patients treated with taladegib had "significant positive differences" in lung volume, overall interstitial lung disease burden and total fibrosis extent.
Deucrictibant XR, a bradykinin B2 antagonist, met the primary and all secondary endpoints in Phase III CHAPTER-3 trial.
The bispecific T-cell engager, in combination with AstraZeneca's Imfinzi, improved overall survival, progression-free survival and overall response rate compared with Imfinzi alone.
Conference News
Industry symposium to explore local delivery of combination antibiotics across spine and arthroplastyPoster showcases the efficacy of STIMULAN® calcium sulfate beads, loaded with a combination of Gram...
WINNIPEG, MB / ACCESS Newswire / September 8, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceutica...
BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological ControlWith Up to 18 Months Fol...
Rapid, deep, and durable pharmacodynamic activity demonstrated across key Type 2 inflammatory biomarkers, including pSTAT6, TARC, eosinophils, and IgE Extended half-life and 85% subcutaneous bioavaila...
Pa-positive NCFB patients experienced a significant reduction in annualised exacerbation rate from 3.4 in the prior 12 months to 1.2 on RESP-X treatmentOnly one exacerbation meeting the Hill/EMBARC cr...
